Innovative Therapieoptionen bei Psoriasis arthropathica: TNFα-Inhibitoren

Summary

Psoriatic arthritis is a spondyloarthritis with negative rheumatoid factor. It can lead to joint destruction and to a mutilant arthritis. A lower quality of life with an increased morbidity and mortality may result. In most cases the single therapy with analgetics is not sufficient. Until now there exist different systemic disease-modifying therapies like methotrexate, sulfasalazine, glucocorticoids or cyclosporine A. New TNFα-inhibitors like infliximab and etanercept demonstrated encouraging results in the therapy of psoriatic arthritis. These agents have proved highly efficient in treating rheumatoid arthritis and slowing progression of joint and bone damage by immunomodulation. Other TNFα-inhibitors like Adalimumab (D2E7) or CDP571 have recently been presented. Here we discuss the present clinical applications and results in research of the therapy of psoriatic arthritis with TNFα-inhibitors.

Literatur

• 1 Blumenauer B, Judd M, Wells G. et al . Infliximab for the treatment of rheumatoid arthritis.  Cochrane Database Syst Rev. 2002;  CD003785
• 2 Brockbank J, Gladmann D. Diagnosis and management of psoriatic arthritis.  Drugs. 2002;  62 2447-2457
• 3 Chaudhari U, Romano P, Mulcahy L D, Dooley L T, Baker D G, Gottlieb A B. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial.  Lancet. 2001;  357 1842-1847
• 4 Culy C R, Keating G M. Etanercept. An updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.  Drugs. 2002;  62 2493-2537
• 5 Gardam M A, Keystone E C, Menzies R. et al . Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.  Lancet Infect Dis. 2003;  3 148-155
• 6 Gladman D D, Farewell V T. Progression in psoriatic arthritis: role of time varying clinical indicators.  J Rheumatol. 1999;  26 2409-2413
• 7 Gottlieb A B, Chaudhari U, Mulcahy L D, Li S, Dooley L T, Baker D G. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis.  J Am Acad Dermatol. 2003;  48 829-835
• 8 Leonardi C L, Powers J L, Matheson R T. et al . Etanercept as monotherapy in patients with psoriasis.  N Engl J Med. 2003;  349 1987-1990
• 9 Lorenz H M, Geiler T. Neue immuntherapeutische Strategien bei Autoimmunerkrankungen.  Dtsch Med Wochenschr. 2001;  126 1023-1028
• 10 Mease P J, Goffe B S, Metz J, VanderStoep A, Finck B, Burge D J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.  Lancet. 2000;  356 385-390
• 11 Mease P J. Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors.  Ann Rheum Dis. 2002;  61 298-304
• 12 Merkesdal S, Ruof J. Betrachtungen zur Kosteneffektivität der Therapie mit TNF-alpha blockierenden Substanzen bei Patienten mit chronischer Polyarthritis.  Z Rheumatol. 2002;  61 29-32
• 13 Puli S R, Benage D D. Retinal vein thrombosis after infliximab (Remicade) treatment for Crohn’s disease.  Am J Gastroenterol. 2003;  98 939-940
• 14 Schopf R E, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab.  J Am Acad Dermatol. 2002;  46 886-891
• 15 Valle E, Gross M, Bickston S J. Infliximab.  Export Opin Pharmacother. 2001;  2 1015-1025